The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Catalyst Pharmaceuticals Inc shares valued at $61,377 were sold by Sundaram Preethi on Jun 10 ’25. At $26.41 per share, Sundaram Preethi sold 2,324 shares. The insider’s holdings dropped to 42,681 shares worth approximately $0.93 million following the completion of this transaction.
Also, Sundaram Preethi sold 1,600 shares, netting a total of over 42,272 in proceeds. Following the sale of shares at $26.42 each, the insider now holds 41,081 shares.
Before that, Sundaram Preethi had added 1,600 shares to its account. In a trade valued at $42,268, the Officer bought Catalyst Pharmaceuticals Inc shares for $26.42 each.
As published in their initiating research note from Robert W. Baird on February 04, 2025, Catalyst Pharmaceuticals Inc [CPRX] has been an Outperform and the price target has been revised to $28. Analysts at Stephens started covering the stock with ‘”an Overweight”‘ outlook in a report released in mid November. As of March 14, 2024, Citigroup has initiated its “Buy” rating for CPRX. Earlier on March 07, 2024, BofA Securities initiated its rating. Their recommendation was “a Buy” for CPRX stock.
Analyzing CPRX Stock Performance
On last trading session,, Catalyst Pharmaceuticals Inc [NASDAQ: CPRX] rose 1.62% to $21.89. The stock’s lowest price that day was $21.4, but it reached a high of $21.89 in the same session. During the last five days, there has been a drop of approximately -4.03%. Over the course of the year, Catalyst Pharmaceuticals Inc shares have jumped approximately 42.24%. Shares of the company reached a 52-week high of $26.58 on 06/09/25 and a 52-week low of $19.15 on 01/08/25.
Support And Resistance Levels for Catalyst Pharmaceuticals Inc (CPRX)
According to the 24-hour chart, there is a support level at 21.51, which, if violated, would cause prices to drop to 21.13. In the upper region, resistance lies at 22.16. The next price resistance is at 22.43. RSI (Relative Strength Index) is 33.25 on the 14-day chart, showing neutral technical sentiment.
Is Catalyst Pharmaceuticals Inc subject to short interest?
Stocks of Catalyst Pharmaceuticals Inc saw a sharp rise in short interest on 2025-06-13 jumping by 0.3 million shares to 7.73 million. Data from Yahoo Finance shows that the short interest on 2025-05-15 was 7.43 million shares. A jump of 3.91% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 6.79 of the overall float, the days-to-cover ratio (short ratio) jumped to 6.79.
Which companies own the most shares of Catalyst Pharmaceuticals Inc (CPRX)?
In terms of Catalyst Pharmaceuticals Inc share price expectations, FactSet research, analysts set an average price target of 33.5 in the next 12 months, up nearly 55.52% from the previous closing price of $21.54. Analysts anticipate Catalyst Pharmaceuticals Inc stock to reach 35 by 2025, with the lowest price target being 32. In spite of this, 3 analysts ranked Catalyst Pharmaceuticals Inc stock as Buy at the end of 2025. On December 21, 2023, Oppenheimer assigned a price target of “an Outperform” to the stock and initiated coverage with a $30.
